A Review on Development of Nano-Carrier Entrapped Vitamin D3-Oral Formulation: A Step Forward in Vitamin D3 Therapy

Abstract

Vitamin D is essential for bone health and supports various non-skeletal functions, including immune response and metabolic regulation. Despite the importance of Vitamin D, Vitamin D deficiency has become a widespread, global issue, with approximately one billion people affected. In India, deficiency rates are alarmingly high, regardless of socio-economic status, age, or geographic location. Traditional Vitamin D supplements often have low bioavailability due to the fat-soluble nature of the vitamin, which limits its absorption in the gastrointestinal tract. Nanotechnology-based Vitamin D formulations, particularly nanoemulsions, offer a solution to this challenge. Nanoemulsions have smaller droplet sizes (<200 nm) that increase the bioavailability and stability of hydrophobic nutrients. Nano-Carrier Entrapped Vitamin D3-Oral formulation, formulated using Aqueol® Nanotechnology, features a stable nanoparticle structure with a size of less than 150 nm. This advanced formulation enhances resistance to digestive enzymes and pH fluctuations, ensuring the efficient delivery of Vitamin D3 directly to the intestinal absorption sites for improved bioavailability. This formulation has shown superior efficacy in clinical trials, with higher and more consistent serum Vitamin D levels compared to traditional formulations. Clinical studies on Nano-Carrier Entrapped Vitamin D3-Oral formulation demonstrate its effectiveness in addressing mechanical low back pain, improving vitamin D levels in children, and reducing inflammatory markers in COVID-19 patients. This formulation represents a promising innovation for overcoming widespread Vitamin D deficiency and may lead to further advancements in nanotechnology-based delivery systems for improved nutrient absorption and bioavailability.